Summary
It has been generally recognized that safety and efficiency tests for drugs are not completed with their admission onto the market. Many undesirable side effects have only been recognized during practical application, such as, for example, in the case of Contergan. Therefore, preventive measures must be taken so that, in case any suspicions arise data for closer checking is available.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Online Conferences Ltd., Uxbridge, England
About this paper
Cite this paper
Hillebrand, J. (1979). Ein Verfahren zur Arzneimittelüberwachung nach ihrer Zulassung. In: Barber, B., Grémy, F., Überla, K., Wagner, G. (eds) Medical Informatics Berlin 1979. Lecture Notes in Medical Informatics, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93120-8_57
Download citation
DOI: https://doi.org/10.1007/978-3-642-93120-8_57
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-09549-1
Online ISBN: 978-3-642-93120-8
eBook Packages: Springer Book Archive